Literature DB >> 11080214

(+)- and (-)-cis-2-aminomethylcyclopropanecarboxylic acids show opposite pharmacology at recombinant rho(1) and rho(2) GABA(C) receptors.

R K Duke1, M Chebib, V J Balcar, R D Allan, K N Mewett, G A Johnston.   

Abstract

The effects of the enantiomers of (+/-)-CAMP and (+/-)-TAMP [(+/-)-cis- and (+/-)-trans-2-aminomethylcyclopropanecarboxylic acids, respectively], which are cyclopropane analogues of GABA, were tested on GABA(A) and GABA(C) receptors expressed in Xenopus laevis oocytes using two-electrode voltage clamp methods. (+)-CAMP was found to be a potent and full agonist at homooligomeric GABA(C) receptors (K:(D) approximately 40 microM: and I:(max) approximately 100% at rho(1); K:(D) approximately 17 microM: and I:(max) approximately 100% at rho(2)) but a very weak antagonist at alpha(1)beta(2)gamma(2L) GABA(A) receptors. In contrast, (-)-CAMP was a very weak antagonist at both alpha(1)beta(2)gamma(2L) GABA(A) receptors and homooligomeric GABA(C) receptors (IC(50) approximately 900 microM: at rho(1) and approximately 400 microM: at rho(2)). Furthermore, (+)-CAMP appears to be a superior agonist to the widely used GABA(C) receptor partial agonist cis-4-aminocrotonic acid (K:(D) approximately 74 microM: and I:(max) approximately 78% at rho(1); K:(D) approximately 70 microM: and I:(max) approximately 82% at rho(2)). (-)-TAMP was the most potent of the cyclopropane analogues on GABA(C) receptors (K:(D) approximately 9 microM: and I:(max) approximately 40% at rho(1); K:(D) approximately 3 microM: and I:(max) approximately 50-60% at rho(2)), but it was also a moderately potent GABA(A) receptor partial agonist (K:(D) approximately 50-60 microM: and I:(max) approximately 50% at alpha(1)beta(2)gamma(2L) GABA(A) receptors). (+)-TAMP was a less potent partial agonist at GABA(C) receptors (K:(D) approximately 60 microM: and I:(max) approximately 40% at rho(1); K:(D) approximately 30 microM: and I:(max) approximately 60% at rho(2)) and a weak partial agonist at alpha(1)beta(2)gamma(2L) GABA(A) receptors (K:(D) approximately 500 micro: and I:(max) approximately 50%). None of the isomers of (+/-)-CAMP and (+/-)-TAMP displayed any interaction with GABA transport at the concentrations tested. Molecular modeling based on the present results provided new insights into the chiral preferences for either agonism or antagonism at GABA(C) receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080214     DOI: 10.1046/j.1471-4159.2000.0752602.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  GABA-ρ receptors: distinctive functions and molecular pharmacology.

Authors:  Moawiah M Naffaa; Sandy Hung; Mary Chebib; Graham A R Johnston; Jane R Hanrahan
Journal:  Br J Pharmacol       Date:  2017-04-12       Impact factor: 8.739

Review 2.  Neurochemicals for the investigation of GABA(C) receptors.

Authors:  Graham A R Johnston; Mary Chebib; Jane R Hanrahan; Kenneth N Mewett
Journal:  Neurochem Res       Date:  2010-10-21       Impact factor: 3.996

3.  trans-4-Amino-2-methylbut-2-enoic acid (2-MeTACA) and (+/-)-trans-2-aminomethylcyclopropanecarboxylic acid ((+/-)-TAMP) can differentiate rat rho3 from human rho1 and rho2 recombinant GABA(C) receptors.

Authors:  Jimmy Vien; Rujee K Duke; Kenneth N Mewett; Graham A R Johnston; Ryuzo Shingai; Mary Chebib
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  Metabolomic Approaches to Defining the Role(s) of GABAρ Receptors in the Brain.

Authors:  Caroline Rae; Fatima A Nasrallah; Vladimir J Balcar; Benjamin D Rowlands; Graham A R Johnston; Jane R Hanrahan
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-11       Impact factor: 4.147

Review 5.  Unsaturated Analogues of the Neurotransmitter GABA: trans-4-Aminocrotonic, cis-4-Aminocrotonic and 4-Aminotetrolic Acids.

Authors:  Graham A R Johnston
Journal:  Neurochem Res       Date:  2015-05-27       Impact factor: 3.996

6.  Novel, potent, and selective GABAC antagonists inhibit myopia development and facilitate learning and memory.

Authors:  Mary Chebib; Tina Hinton; Katrina L Schmid; Darren Brinkworth; Haohua Qian; Susana Matos; Hye-Lim Kim; Heba Abdel-Halim; Rohan J Kumar; Graham A R Johnston; Jane R Hanrahan
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

7.  Guanidino acids act as rho1 GABA(C) receptor antagonists.

Authors:  Mary Chebib; Navnath Gavande; Kit Yee Wong; Anna Park; Isabella Premoli; Kenneth N Mewett; Robin D Allan; Rujee K Duke; Graham A R Johnston; Jane R Hanrahan
Journal:  Neurochem Res       Date:  2009-04-23       Impact factor: 3.996

8.  Mixed antagonistic effects of the ginkgolides at recombinant human ρ1 GABAC receptors.

Authors:  Shelley H Huang; Trevor M Lewis; Sarah C R Lummis; Andrew J Thompson; Mary Chebib; Graham A R Johnston; Rujee K Duke
Journal:  Neuropharmacology       Date:  2012-07-22       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.